Skip to main content
Top
Published in: Dermatology and Therapy 2/2018

Open Access 01-06-2018 | Original Research

Effect of Topical Steroids on Skin Prick Test: A Randomized Controlled Trial

Authors: Anne R. Ebbesen, Lene A. Riis, Josefine Gradman

Published in: Dermatology and Therapy | Issue 2/2018

Login to get access

Abstract

Introduction

Topically applied corticosteroids on the skin can significantly inhibit the wheal response to allergens in skin prick test (SPT). The duration of this effect is unknown. The aim of this study is to investigate the duration of the inhibitory effect of topical corticosteroids on SPT.

Methods

Twenty-two healthy subjects were included in a single-blinded randomized study. All subjects were skin prick tested using a standard inhalant allergen panel. The subjects were randomized to treat either the left or right forearm with Betnovat® cream (group III steroid) once a day for 10 days. Subsequently, the subjects were skin prick tested the following 5 days and at day 8 on both forearms.

Results

At baseline, the 22 individuals had positive SPT for a total of 72 allergens. Compared with the untreated arm, the mean size of the wheals was significantly reduced on day 1 (12 h after end of treatment) by 0.56 mm (95 % confidence interval (CI) [0.06; 1.06], p = 0.03) for allergens and 0.70 mm [0.32; 1.09] (p = 0.001) for histamine. On day 2 (36 h after end of treatment), the mean difference between treated and untreated arm was 0.47 mm [−0.08; 0.85] (p = 0.02) for allergen-induced wheals and 0.22 mm [−0.21; 0.64] (p = 0.31) for histamine-induced wheal. On day 3, 4, 5, and 8, there was no significant difference.

Conclusions

Treatment with topical steroid significantly inhibited the response to SPT for 36 h but for less than 3 days. In addition, we demonstrated that topical applied corticosteroids inhibit the mean wheal size of the positive histamine control for a shorter time than for the allergens. Consequently, positive response to histamine control is not a valid marker for reliable skin prick test in steroid-treated patients.

Plain Language Summary

Plain language summary available for this article.
Literature
1.
go back to reference Blackley CH. Hay fever: its causes, treatment, and effective prevention; experimental researches. 2nd ed. London: Bailliere, Tindall and Cox; 1880. Blackley CH. Hay fever: its causes, treatment, and effective prevention; experimental researches. 2nd ed. London: Bailliere, Tindall and Cox; 1880.
2.
go back to reference Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, Bousquet PJ, Burney PG, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67(1):18–24.CrossRefPubMed Bousquet J, Heinzerling L, Bachert C, Papadopoulos NG, Bousquet PJ, Burney PG, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67(1):18–24.CrossRefPubMed
3.
go back to reference Grabenhenrich LB, Keil T, Reich A, Gough H, Beschorner J, Hoffmann U, Bauer CP. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol. 2015;136(4):932–40.CrossRefPubMed Grabenhenrich LB, Keil T, Reich A, Gough H, Beschorner J, Hoffmann U, Bauer CP. Prediction and prevention of allergic rhinitis: a birth cohort study of 20 years. J Allergy Clin Immunol. 2015;136(4):932–40.CrossRefPubMed
4.
go back to reference Pipkorn U, Hammarlund A, Enerbäck L. Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced wheal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin Exp All. 1989;19(1):19–25.CrossRef Pipkorn U, Hammarlund A, Enerbäck L. Prolonged treatment with topical glucocorticoids results in an inhibition of the allergen-induced wheal-and-flare response and a reduction in skin mast cell numbers and histamine content. Clin Exp All. 1989;19(1):19–25.CrossRef
5.
go back to reference Andersson M, Pipkorn U. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids. J Allergy Clin Immunol. 1987;79(2):345–9.CrossRefPubMed Andersson M, Pipkorn U. Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids. J Allergy Clin Immunol. 1987;79(2):345–9.CrossRefPubMed
6.
8.
go back to reference Shah KM, Rank MA, Dave SA, Oslie CL, Butterfield JH. Predicting which medication classes interfere with allergy skin testing. Allergy Asthma Proc. 2010;31(6):477–82.CrossRefPubMed Shah KM, Rank MA, Dave SA, Oslie CL, Butterfield JH. Predicting which medication classes interfere with allergy skin testing. Allergy Asthma Proc. 2010;31(6):477–82.CrossRefPubMed
9.
go back to reference Narasimha SK, Srinivas CR, Mathew AC. Effect of topical corticosteroid application frequency and histamine induced wheals. Int J Dermatol. 2005;44(5):425–7.CrossRefPubMed Narasimha SK, Srinivas CR, Mathew AC. Effect of topical corticosteroid application frequency and histamine induced wheals. Int J Dermatol. 2005;44(5):425–7.CrossRefPubMed
10.
go back to reference Gradman J, Wolthers OD. Suppressive effects of topical mometasone furoate and tacrolimus on skin prick testing in children. Pediatr Dermatol. 2008;25(2):269–70.CrossRefPubMed Gradman J, Wolthers OD. Suppressive effects of topical mometasone furoate and tacrolimus on skin prick testing in children. Pediatr Dermatol. 2008;25(2):269–70.CrossRefPubMed
11.
go back to reference Spergel JM, Taylor P, Parneix Spake A. Effect of topical pimecrolimus on epicutaneous skin testing. J Allergy Clin Immunol. 2004;114(3):695–7.CrossRefPubMed Spergel JM, Taylor P, Parneix Spake A. Effect of topical pimecrolimus on epicutaneous skin testing. J Allergy Clin Immunol. 2004;114(3):695–7.CrossRefPubMed
12.
go back to reference Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64(Suppl 91):1–59.PubMed Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64(Suppl 91):1–59.PubMed
13.
go back to reference Skassa-Brociek W, Manderscheid JC, Michel FB, Bousquet J. Skin test reactivity to histamine from infancy to old age. J Allergy Clin Immunol. 1987;80(5):711–6.CrossRefPubMed Skassa-Brociek W, Manderscheid JC, Michel FB, Bousquet J. Skin test reactivity to histamine from infancy to old age. J Allergy Clin Immunol. 1987;80(5):711–6.CrossRefPubMed
14.
go back to reference Pearlman DS, Grossman J, Meltzer EO. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(3):528–62.CrossRef Pearlman DS, Grossman J, Meltzer EO. Histamine skin test reactivity following single and multiple doses of azelastine nasal spray in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(3):528–62.CrossRef
Metadata
Title
Effect of Topical Steroids on Skin Prick Test: A Randomized Controlled Trial
Authors
Anne R. Ebbesen
Lene A. Riis
Josefine Gradman
Publication date
01-06-2018
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 2/2018
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-018-0238-1

Other articles of this Issue 2/2018

Dermatology and Therapy 2/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.